Pulmonx Corporation (LUNG)
| Market Cap | 2.34B |
| Revenue (ttm) | 31.74M |
| Net Income (ttm) | -28.08M |
| Shares Out | 32.47M |
| EPS (ttm) | -0.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $65.86 |
| Previous Close | $62.94 |
| Change ($) | 2.92 |
| Change (%) | 4.64% |
| Day's Open | 62.50 |
| Day's Range | 59.33 - 66.13 |
| Day's Volume | 86,132 |
| 52-Week Range | 39.31 - 69.02 |
Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company's Initial Public Offering Georgia Garinois-Melenikiotou and Thomas W. Burns...
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
The Zephyr Valve Helps COPD/Emphysema Patients Breathe Easier Without the Risk of Major Surgery 1
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment...
REDWOOD CITY, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor confer...
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas Positive Coverage Policy from He...
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that ...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
REDWOOD CITY, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatme...
Shares of Pulmonx, a maker of treatments for lung diseases including emphysema, rose 118% in their trading debut Thursday, after the company's initial public offering priced above range. The d...
Pulmonx, a maker of treatments for lung diseases including emphysema, priced its initial public offering at $19 a share, above its proposed price range of $17 to $18.
REDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common s...
Pulmonx, a maker of treatments for lung diseases including emphysema, upsized its planned initial public offering on Wednesday and raised the proposed price range, saying in a regulatory filin...
About LUNG
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also prov... [Read more...]
| Industry Surgical and Medical Instrument Manufacturing | IPO Date Oct 1, 2020 |
| CEO Glendon E. French | Employees 180 |
| Stock Exchange NASDAQ | Ticker Symbol LUNG |
Financial Performance
In 2019, Pulmonx's revenue was $32.60 million, an increase of 62.94% compared to the previous year's $20.00 million. Losses were -$20.70 million, 12.0% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Pulmonx stock is "Buy." The 12-month stock price forecast is 53.80, which is a decrease of -18.31% from the latest price.